Sarepta Therapeutics Inc
After a long regulatory process filled with delays and intense speculation, FDA approved Sarepta Therapeutics Inc’s (NASDAQ:SRPT) Exondys 51 (eteplirsen) for the treatment of Duchenne Muscular Dystrophy (DMD).
In reaction, WBB Securities analyst Stephen Brozak raised his price target from $40 to $60, while reiterating a Strong Buy rating on SRPT.
Brozak noted, “The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) from Sarepta Therapeutics, Inc. (SRPT) under accelerated approval provisions. Exondys 51 is the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD. We are therefore reiterating our Strong Buy Recommendation of SRPT and increasing our One-Year Price Target to $60.00.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Stephen Brozak has a yearly average return of 26.5% and a 62.5% success rate. Brozak has a 14.9% average return when recommending SRPT, and is ranked #233 out of 4163 analysts.
Out of the 15 analysts polled by TipRanks, 7 rate Sarepta stock a Buy, 5 rate the stock a Hold and 3 recommend a Sell. With a downside potential of 50%, the stock’s consensus target price stands at $27.17.
Today, FBN analyst Shebly Seyrafi reiterated a Sector Perform rating on shares GoPro Inc (NASDAQ:GPRO), while raising the price target for the stock to $15 (from $13), after the action camera maker unveiled its HERO5 Black, the HERO5 Session, and Karma (its first drone).
Seyrafi commented, “What impressed us most were the video stabilization features added to its HERO5 Black, HERO5 Session (but not the prior generation HERO Session), and Karma […] A concern is that the new HERO5 Black, at $399, will be priced $50 to $100 below the prior HERO4 Black price of $449.99 to $499.99. Offsetting this somewhat is that there will not be a HERO5 Silver (at least for the time being), and since before the majority of GPRO cameras at price points above $399 were Silver (vs. Black), the net negative impact on ASPs (vs. our model, which already had ASPs coming down) could be minimal.”
“The company is pricing the HERO5 Session at $299.99, a hundred dollars higher than the HERO Session, since the HERO5 Session has video stabilization features and the ability to automatically upload to the cloud. However, we believe that this price point may be too high and that the company may lower this price point in the future (just as it did with the HERO Session over the past year). Karma will face strong competition from DJI, whose Phantom 4 goes for $1,199, but Karma will not have Follow-Me or Object Avoidance “for now”,” the analyst added.
According to TipRanks.com, analyst Shebly Seyrafi has a yearly average return of 0.9% and a 52% success rate. Seyrafi has a -68.1% average return when recommending GPRO, and is ranked #1662 out of 4163 analysts.
TipRanks analytics exhibits GPRO as a Hold with 7 analysts issuing a Hold rating for the stock, 2 maintaining a Buy rating, and the remaining 2 upholding a Sell rating. The consensus target price for GPRO is $11.88, marking a 22.50% downside from current prices.